Literature DB >> 24366973

Towards a genomic definition of completeness of resection?

Michael A Vogelbaum1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24366973      PMCID： PMC3870827          DOI： 10.1093/neuonc/not231

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  12 in total

Review 1.  Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors.

Authors:  R Sawaya; M Hammoud; D Schoppa; K R Hess; S Z Wu; W M Shi; D M Wildrick
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

2.  Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.

Authors:  G Evren Keles; Edward F Chang; Kathleen R Lamborn; Tarik Tihan; Chih-Ju Chang; Susan M Chang; Mitchel S Berger
Journal:  J Neurosurg       Date:  2006-07       Impact factor: 5.115

3.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

4.  Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; D F Nelson; A J Fischbach; C H Chang; M Rotman; S O Asbell
Journal:  J Neurooncol       Date:  1992-03       Impact factor: 4.130

5.  Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article.

Authors:  Walter Stummer; Jörg-Christian Tonn; Hubertus Maximilian Mehdorn; Ulf Nestler; Kea Franz; Claudia Goetz; Andrea Bink; Uwe Pichlmeier
Journal:  J Neurosurg       Date:  2010-04-16       Impact factor: 5.115

6.  An extent of resection threshold for newly diagnosed glioblastomas.

Authors:  Nader Sanai; Mei-Yin Polley; Michael W McDermott; Andrew T Parsa; Mitchel S Berger
Journal:  J Neurosurg       Date:  2011-03-18       Impact factor: 5.115

7.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Authors:  M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

Review 8.  Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.

Authors:  Michael A Vogelbaum; Sarah Jost; Manish K Aghi; Amy B Heimberger; John H Sampson; Patrick Y Wen; David R Macdonald; Martin J Van den Bent; Susan M Chang
Journal:  Neurosurgery       Date:  2012-01       Impact factor: 4.654

9.  Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme.

Authors:  Matthew J McGirt; Debraj Mukherjee; Kaisorn L Chaichana; Khoi D Than; Jon D Weingart; Alfredo Quinones-Hinojosa
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

10.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas.

Authors:  Justin S Smith; Edward F Chang; Kathleen R Lamborn; Susan M Chang; Michael D Prados; Soonmee Cha; Tarik Tihan; Scott Vandenberg; Michael W McDermott; Mitchel S Berger
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544
View more
  1 in total

Review 1.  The surgical perspective in precision treatment of diffuse gliomas.

Authors:  Niklas Thon; Joerg-Christian Tonn; Friedrich-Wilhelm Kreth
Journal:  Onco Targets Ther       Date:  2019-02-22       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.